|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Biochemical control, distant metastasis-free survival (DMFS), prostate cancer-specific survival (PCSS), and overall survival (OS) were compared between those who achieved a nadir PSA ≤0.5 ng/mL with those who did not via Kaplan-Meier analysis.
|
30112266 |
2018 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Effects of the MTHFR C677T polymorphism on prostate specific antigen and prostate cancer.
|
22296369 |
2011 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Two of the classical kallikrein genes KLK3 and KLK2 on 19q13.4 are plausible candidates in prostate cancer susceptibility.
|
17593395 |
2007 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
MRI-guided transperineal prostate biopsy was performed on 78 patients who had presented to our hospital with a prostate-specific antigen level >4 ng/mL or with MRI scans suggesting prostate cancer between January 2015 and August 2017.
|
30964117 |
2019 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We developed a frailty model where only a proportion of the population could develop prostate cancer, and where the increased risk of diagnosis due to the massive use of PSA testing was modelled by encompassing this heterogeneity in risk.
|
27431530 |
2017 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The PSA -158 G/A polymorphism was determined by PCR amplification and restriction digestion assays in 101 organ-confined prostate cancer (PC) patients who underwent radical prostatectomy and 52 controls with benign prostatic hyperplasia.
|
17094454 |
2006 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
In all, 155 patients diagnosed with prostate cancer and 195 controls with negative digital rectal examinations and PSA levels of <4 ng/dL were enrolled in this study.
|
23773345 |
2013 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Nearly half of men aged 60+ yr with elevated PSA had a four-kallikrein panel score of <7.5%, translating into 1.7% risk of prostate cancer death at 15 yr-a similar estimate to that of a man with a PSA of 1.6ng/ml.
|
29519548 |
2018 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The PSA -158A/G polymorphism is associated with prostate cancer.
|
15017213 |
2004 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
To determine the association among prostate cancer gene 3 (PCA3) score, Prostate Imaging Reporting and Data System (PI-RADS) grade and Gleason score, in a cohort of patients with elevated prostate-specific antigen (PSA), undergoing magnetic resonance imaging/ultrasonography fusion software-based targeted prostate biopsy (TBx) after a previous negative randomised 'standard' biopsy (SBx).
|
27112799 |
2016 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The PSA level and age at study entry were associated with PrCa at PB (p = .00037 and p = .00004, respectively).
|
27151655 |
2016 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
T2E transcripts were detected in 31.7% (n=20) of the patients examined, and this was significantly associated with subsequent detection of PC in ASAP patients with a prostate specific antigen (PSA) level of 4-10ng/ml (p=0.045).
|
29277318 |
2018 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
In this randomised trial, we tested whether chemotherapy after surgery for high-risk prostate cancer decreases the risk of a rising prostate-specific antigen.
|
29395502 |
2018 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
For each 5-percentage point decrease in PSA screening among men aged 70 and older for a single calendar year, total costs associated with prostate cancer screening decreased by 13.8%.
|
29743049 |
2018 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Recently, the rs61752561 SNP (Asp84Asn substitution) in exon 3 of the kallikrein-related peptidase 3 (<i>KLK3</i>) gene encoding prostate-specific antigen (PSA) was reported to be strongly associated with PCa risk (<i>P</i> = 2.3 × 10<sup>-8</sup>).
|
30538125 |
2019 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Our preliminary experience suggests that performing <sup>68</sup> Ga-PSMA PET/CT in patients with prostate cancer with rising PSA after treatment with curative intent can be clinically useful as it changes the treatment strategy in a significant proportion of patients.
|
27981732 |
2017 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Excluded were men with history of prostate carcinoma (CaP), <6 or ≥24 bx cores, and/or prostate-specific antigen (PSA) level ≥50 ng/mL, resulting in 1909 included men.
|
25443926 |
2014 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Cox regression models, adjusted for age, clinical stage, pathologic grade, nodal or distant metastases, and diagnostic serum levels of prostate-specific antigen level, were used to assess association between risk variants and prostate cancer-specific survival.
|
19423541 |
2009 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Important randomized trials show a clear benefit to androgen deprivation therapy (ADT) in both intermediate-risk prostate cancer and postprostatectomy patients with rising PSA.
|
29465428 |
2018 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
SigPCa probabilities were calculated with the two PSA measures using ERSPC3/4+digital rectal examination and PCPT v2+free PSA RCs.
|
31722940 |
2019 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Validation of association of genetic variants at 10q with prostate-specific antigen (PSA) levels in men at high risk for prostate cancer.
|
23937305 |
2014 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Following years of controversy regarding screening for prostate cancer using prostate-specific antigen, evidence evolves towards a more restrained and preference-based use.
|
31194773 |
2019 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
ERG, SLC45A3 and PTEN immunostaining and their association with pathological features and PSA progression-free survival were analyzed in 220 PrCa (PSMAR-Biobank, Barcelona, Spain).
|
29088771 |
2017 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The following clinical variables were included in the analysis: age, clinical tumor, node, metastasis stage, Gleason score, risk groups of prostate cancer, prostate-specific antigen (PSA) at the initiation of ADT, PSA nadir after ADT, velocity of PSA decline, and the time to PSA nadir.
|
28885333 |
2017 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Human (PC3, DU145) and rat (AT2, AT6) prostate cancer cell lines were transfected with the full PSA gene encoding preproPSA protein.
|
12746846 |
2003 |